Plasminogen activator inhibitor-1 [PAI-1] gene 4G-5G promoter polymorphism in subjects with cancer

• Autorzy: Smolarz B. , Blasiak J. , Piestrzeniewicz D. , Pytel J.
• Języki publikacji: EN

Abstrakty

EN

Plasminogen activator inhibitor PAI-1 is a fast-acting controlling factor of the plasminogen activator system. The system contains proteolytic enzymes that may contribute to cancer cell invasion by degrading the surrounding extracellular matrix and dissociate cell-cell or cell-matrix attachments. There is substantial evidence in many types of cancer that the antigen content of PAI-1 in primary cancer tissue extracts are of strong prognostic value: high level of PAI-1 in tumor predict poor prognosis for the patient. Moreover, it was demonstrated that the level of PAI-1 in metastasis is significantly higher compared to primary tumors. An insertion/deletion polymorphism in the promoter of the PAI-1 gene has been described that relates to plasma PAI-1 levels. We studied this polymorphism in the plasma of subjects with cancer. Blood was taken from 23 patients (10 breast cancers, 5 gastric cancers, 4 head and neck cancers, 2 melanomas and 2 colorectal cancers) and 23 matched controls. Although frequencies of the 4G and 5G alleles were approximately 0.5/0.5 in both patients and controls, the genotype distribution differed significantly between the two groups - the 4G/5G genotype was observed more frequently in patients with cancer than in the controls. Further studies are needed to check whether the prevalence of the 4G/5G genotype may influence an individual’s plasminogen activation system capacity and thereby contribute in a small way to the cancer risk profile.

Słowa kluczowe

EN

plasminogen activator system; cell invasion; metastasis; physiological function; proteolytic enzyme; plasminogen activator inhibitor; gene; polymorphism; antigen; genotype; tumour; cancer; inhibitor

• Wydawca: -
• Czasopismo: Cellular and Molecular Biology Letters
• Rocznik: 1998
• Tom: 03
• Numer: 1
• Opis fizyczny: p.49-56,fig.

Twórcy

autor

Smolarz B.

• University of Lodz, Lodz, Poland

autor

Blasiak J.

autor

Piestrzeniewicz D.

autor

Pytel J.

Bibliografia

• 1. Mayer, M. Clin. Biochem. 23 (1990) 197-211.
• 2. Collen, D. and Lijnen, H. R. Blood 78 (1991) 3114-3124.
• 3. Plesner, T., Behrendt, M. and Ploug, M. Stem Cells 15 (1997) 398-408.
• 4. Andreasen, P. A., Georg, B., Lund, L. R., Riccio, A. and Stacey, S. N. Mol. Cell. Endocrinol. 68 (1990) 1-19.
• 5. Heaton, J. H., Kathju, S. and Gelehrter, T. D. Mol. Endocrinol. 6 (1992) 53-60.
• 6. Healy, A. M. and Gelehrter, T. D. J. Biol. Chem. 269 (1994) 19095-19100.
• 7. Liotta, L. A. Cancer Res. 46 (1986) 1-7.
• 8. Cohen, R. L., Xiao-Ping, X., Crowley, C. W., Lucas, B. K., Levinson, A. D. and Shuman, M. A. Blood 78 (1991) 479-487.
• 9. Andreasen, P. a., Kjoller, L., Christensen, L. and Duffy, M. J. Int. J. Cancer 72 (1997) 1-22.
• 10. Janicke, F., Schmitt, M., Pache, L., Ulm, K., Harbeck, N., Hofier, H. and Graeff, H. Breast Cancer Res. Treat. 24 (1993) 195-208.
• 11. Foekens, J. A., Schmitt, M., van Putten, W. L. J., Peters, H. A., Kramer, M. D., Janicke, F. and Klijn, J. G. M. J. Clin. Oncol. 12 (1994) 1648-1658.
• 12. Grondahl-Hansen, J., Christensen, I. J., Rosenquist, C., Brunner, N., Mouridsen, H. T., Dano, K. and Blichert-Tofit, M. Cancer Res. 53 (1993) 2513-2521.
• 13. Nekarda, H., Siewert, J., Schmitt, M. and Ulm, K. Lancet 343 (1994) 117.
• 14. Farinati, F., Herszenyi, L., Plewbani, M., Carraro, P., De Paoli, M., Cardin, R., Roveroni, G., Rugge, M., Nitti, D., Grigioni, W. F., D’Errico, A. and Naccarato, R. Carcinogenesis 17 (1996) 2581-2587.
• 15. Pedersen, H., Grondahl-Hansen, J., Francis, D., Osterlind, K., Hansen, H. H., Dano, K. and Brunner, N. Cancer Res. 54 (1994) 120-123.
• 16. Kuhn, W., Pache, L., Schmalfeldt, B., Dettmar, P., Schmitt, M., Janicke, F. and Graeff, H. Gynecol. Oncol. 55 (1994) 401-409.
• 17. Soff, G. A., Sanderowitz, J., Gately, S., Verrusio, E., Weiss, I., Brem, S. and Kwaan, H. C. J. Clin. Invest. 96 (1995) 2593-2602.
• 18. Alizadeh, H., Ma, D., Berman, M., Bellingham, D., Comerford, S. A., Gething, M-J. H., Sambrook, J. F. and Niederkorm, J. Y. Curr. Eye Res. 14 (1995) 449-461.
• 19. Tran-Thang, C., Kruithof, E. K. O., Lahm, H., Schuster, W-A., Tada, M. and Sordat, B. Br. J. Cancer 74 (1996) 846-852.
• 20. Loskutoff, D. J. Fibrynolysis 5 (1991) 197-206.
• 21. Henry, M., Chomiki, N., Scarabin, P. Y., Alessi, M. C., Peiretti, F., Arveiler, D., Ferrieres, J., Evans, A., Amouyel, P., Poirier, O., Cambien, F. and Juhan-Vague, I. Arterioscler. Thromb. Vase. Biol. 17 (1997) 851-858.
• 22. Mansfield, M. W., Strickland, M. H., Carter, A. M., and Grant, P. J. Thromb. Haemost. 71 (1994) 731-736.
• 23. Dawson, S., Hamsten, A., Wiman, B., Henney, A. and Humphries, S. Arterioscler. Thromb. 11 (1991) 183-190.
• 24. Klinger, K. W., Winqvist, R., Riccio, A., Andreasen, P. A., Sartorio, R., Nielsen, L. S., Stuart, N., Stanislovitis, P., Watkins, P., Douglas, R., Grzeschik, K. H. and Alitalo, K. Proc. Natl. Acad. Sci. USA 84 (1991) 8548-8552.
• 25. Dawson, S., Wiman, B., Hamsten, A., Green, F., Humphries, S., Henney, A. M. J. Biol. Chem. 268 (1993) 10739-10745.
• 26. Falk, G., Almqvist, A., Nordehen, A., Svensson, H. and Wiman, B. Fibrinolysis 9 (1995) 170-174.
• 27. Juhan-Vague, I. Atherosclerosis 124 (1996) S49-S55.
• 28. Eriksson, P., Kallin, B., Van’t Hooft, F. and Hamsten, A. Fibrinolysis 8 (1994) 79-94.
• 29. Panahloo, A., Mohamed-Ali, V., Lane, A., Green, F., Humphries, S. and Yudkin, J. Diabetes 44 (1995) 37-42.
• 30. Juhan-Vague, I. and Alessi, M. C. Thromb. Haemost. 70 (1993) 138-149.
• 31. McGill, J. B., Schneider, D. J., Arfken, C. L., Lucore, C. L., Sobel, B. E. Diabetes 43 (1994) 104-115.
• 32. Eriksson, P., Kallin, B., Van’t Hooft, F. M., Bavenholm, P. and Hamsten, A. Proc. Natl. Acad. Sci. USA 92 (1995) 1851-1855.
• 33. McCormack, L. J., Nagi, D. K., Stickland, M. H., Mansfield, M. W., Mohamed-Ali, V., Yudkin, J. S., Knowler, W. C. and Grant P. J. Diabetologia 39 (1996) 1512-1518.